I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Emma N. Walmsley net worth and biography

Emma Walmsley Biography and Net Worth

CEO & Director of GSK

Emma has been GSK CEO and Board Director since April 2017. Emma has been a member of the GSK Leadership Team since 2011, as the President and then CEO of GSK Consumer Healthcare.

Prior to joining GSK in 2010, Emma worked with L’Oreal for 17 years in global and local marketing and general management roles in Paris, London, New York and Shanghai.

Emma joined the Microsoft board as an independent director in 2019. She was previously a Non-Executive Director of Diageo plc. She is a Member of the Stanford Medicine Board of Fellows.

Emma is a business advisor to the UK Prime Minister and a member of The Business Council Executive Committee in the US.

Emma ranked top in Fortune Magazine’s 2020 ‘Most Powerful International Women’.

Emma was appointed Dame Commander of the British Empire for services to the pharmaceutical industry and business in 2020.

Emma holds an MA in Classics and Modern Languages from Oxford University.

How old is Emma N. Walmsley?: Ms. Walmsley is currently 55 years old. There are 3 older executives and no younger executives at GSK. The oldest executive at GSK is Ms. Julie Belita Brown, CFO & Executive Director, who is 62 years old. Learn More on Emma N. Walmsley's age.
How do I contact Emma N. Walmsley?: The corporate mailing address for Ms. Walmsley and other GSK executives is 980 GREAT WEST ROAD, BRENTFORD X0, TW8 9GS. GSK can also be reached via phone at 442080475000 and via email at [email protected]. Learn More on Emma N. Walmsley's contact information.
Has Emma N. Walmsley been buying or selling shares of GSK?: Emma N. Walmsley has not been actively trading shares of GSK during the last ninety days. Learn More on Emma N. Walmsley's trading history.
Who are GSK's active insiders?: GSK's insider roster includes Sally Jackson (Sr. VP of Global Communications & CEO Office), Iain Mackay (CFO & Exec. Director ), and Emma Walmsley (CEO & Director ). Learn More on GSK's active insiders.
Are insiders buying or selling shares of GSK?: During the last year, GSK insiders bought shares 1 times. They purchased a total of 2,791,930 shares worth more than $22,335,440.00. The most recent insider tranaction occured on September, 27th when Major Shareholder Plc Gsk bought 2,791,930 shares worth more than $22,335,440.00. Insiders at GSK own 10.0% of the company. Learn More about insider trades at GSK.
Information on this page was last updated on 9/27/2024.

Emma N. Walmsley Insider Trading History at GSK

Emma N. Walmsley Buying and Selling Activity at GSK

GSK Company Overview

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Today's Range

Now: $33.35

$32.83

$33.50

50 Day Range

MA: $39.08

$33.35

$44.09

2 Week Range

Now: $33.35

$32.83

$45.92

Volume

13,747,891 shs

Average Volume

7,092,211 shs

Market Capitalization

$69.12 billion

P/E Ratio

21.66

Dividend Yield

4.62%

Beta

0.66

I was wrong. Dead wrong.

From Porter & Company | Ad